Oruka Therapeutics, Inc. Operating Lease, Payments
Oruka Therapeutics, Inc. (ORKA) reported Operating Lease, Payments of $382.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-10
- Oruka Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $196.00K, a 133.33% increase year-over-year.
- Oruka Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $186.00K, a 195.24% increase year-over-year.
- Oruka Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $43.00K.
- Oruka Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $510.00K.
- Oruka Therapeutics, Inc. operating lease, payments for fiscal 2025 was $700.00K.
- Oruka Therapeutics, Inc. operating lease, payments for fiscal 2023 was $127.00K, a 3.05% decline from fiscal 2022.
- Oruka Therapeutics, Inc. operating lease, payments for fiscal 2022 was $131.00K, a 55.95% increase from fiscal 2021.
- Oruka Therapeutics, Inc. operating lease, payments for fiscal 2021 was $84.00K, a 0.00% change from fiscal 2020.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 8 month | Operating Lease, Payments 9 month | Operating Lease, Payments 11 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $196.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $382.00K 10-Q · filed 2026-08-10 | $425.00K derived: sum of 3 quarters · filed 2026-08-10 | $935.00K derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $186.00K 10-Q · filed 2026-05-13 | $229.00K derived: sum of 2 quarters · filed 2026-05-13 | $739.00K derived: sum of 3 quarters · filed 2026-05-13 | $823.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2025-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $553.00K derived: sum of 2 quarters · filed 2026-03-12 | $637.00K derived: sum of 3 quarters · filed 2026-03-12 | $700.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $594.00K derived: sum of 2 quarters · filed 2025-11-12 | $657.00K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $147.00K 10-Q · filed 2025-08-11 | |||||
| 2025-03-31 | $63.00K 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | $116.00K 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | $74.00K 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $47.00K 10-Q · filed 2024-08-01 | $73.00K derived: sum of 3 quarters · filed 2024-08-01 | $107.00K derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2024-03-31 | $23.00K 10-Q · filed 2024-04-25 | $49.00K derived: sum of 2 quarters · filed 2024-04-25 | $83.00K derived: sum of 3 quarters · filed 2024-04-25 | $117.00K derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-01 | $60.00K derived: sum of 2 quarters · filed 2024-02-01 | $94.00K derived: sum of 3 quarters · filed 2024-08-01 | $127.00K 10-K · filed 2024-02-01 | |||
| 2023-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-18 | $68.00K derived: sum of 2 quarters · filed 2024-08-01 | $101.00K 10-Q · filed 2023-10-18 | $134.00K derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2023-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $67.00K 10-Q · filed 2024-08-01 | $100.00K derived: sum of 3 quarters · filed 2024-08-01 | $133.00K derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2023-03-31 | $33.00K 10-Q · filed 2024-04-25 | $66.00K derived: sum of 2 quarters · filed 2024-04-25 | $99.00K derived: sum of 3 quarters · filed 2024-04-25 | $132.00K derived: sum of 4 quarters · filed 2024-04-25 | |||
| 2022-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-01 | $66.00K derived: sum of 2 quarters · filed 2024-02-01 | $99.00K derived: sum of 3 quarters · filed 2024-02-01 | $131.00K 10-K · filed 2024-02-01 | |||
| 2022-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-18 | $66.00K derived: sum of 2 quarters · filed 2023-10-18 | $98.00K 10-Q · filed 2023-10-18 | $130.00K derived: sum of 4 quarters · filed 2023-10-18 | |||
| 2022-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-21 | $65.00K 10-Q · filed 2023-07-21 | $97.00K derived: sum of 3 quarters · filed 2023-07-21 | $120.00K derived: sum of 4 quarters · filed 2023-07-21 | |||
| 2022-03-31 | $32.00K 10-Q · filed 2023-04-24 | $64.00K derived: sum of 2 quarters · filed 2023-04-24 | $87.00K derived: sum of 3 quarters · filed 2023-04-24 | $109.00K derived: sum of 4 quarters · filed 2023-04-24 | |||
| 2021-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $55.00K derived: sum of 2 quarters · filed 2023-02-24 | $77.00K derived: sum of 3 quarters · filed 2023-02-24 | $84.00K 10-K · filed 2023-02-24 | |||
| 2021-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $45.00K derived: sum of 2 quarters · filed 2022-10-28 | $52.00K 10-Q · filed 2022-10-28 | $60.00K derived: sum of 4 quarters · filed 2022-10-28 | |||
| 2021-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $29.00K 10-Q · filed 2022-08-02 | $37.00K derived: sum of 3 quarters · filed 2022-08-02 | $62.00K derived: sum of 4 quarters · filed 2022-08-02 | |||
| 2021-03-31 | $7.00K 10-Q · filed 2022-05-02 | $15.00K derived: sum of 2 quarters · filed 2022-05-02 | $40.00K derived: sum of 3 quarters · filed 2022-05-02 | $66.00K derived: sum of 4 quarters · filed 2022-05-02 | |||
| 2020-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $33.00K derived: sum of 2 quarters · filed 2022-03-14 | $59.00K derived: sum of 3 quarters · filed 2022-03-14 | $84.00K 10-K · filed 2022-03-14 | $76.00K 10-K · filed 2021-03-18 | ||
| 2020-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $51.00K derived: sum of 2 quarters · filed 2021-11-02 | $76.00K 10-Q · filed 2021-11-02 | $84.00K derived: sum of 4 quarters · filed 2022-03-14 | |||
| 2020-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $51.00K 10-Q · filed 2021-08-04 | $59.00K derived: sum of 3 quarters · filed 2022-03-14 | $82.00K derived: sum of 4 quarters · filed 2022-03-14 | |||
| 2020-03-31 | $25.00K 10-Q · filed 2021-05-11 | $33.00K derived: sum of 2 quarters · filed 2022-03-14 | $56.00K derived: sum of 3 quarters · filed 2022-03-14 | $78.00K derived: sum of 4 quarters · filed 2022-03-14 | |||
| 2019-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $31.00K derived: sum of 2 quarters · filed 2022-03-14 | $53.00K derived: sum of 3 quarters · filed 2022-03-14 | $76.00K 10-K · filed 2022-03-14 | $91.00K 10-K · filed 2020-02-18 | ||
| 2019-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $45.00K derived: sum of 2 quarters · filed 2020-11-02 | $68.00K 10-Q · filed 2020-11-02 | ||||
| 2019-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $45.00K 10-Q · filed 2020-08-05 | |||||
| 2019-03-31 | $23.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |